Stefan Oelrich has been a member of the Board of Management of Bayer AG and Head of the Pharmaceuticals Division, headquartered in Berlin, Germany, since November 2018. He is also responsible for the region Latin America. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held several positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Oelrich returned to the United States as Senior Vice President and General Manager of Women’s Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Oelrich became head of Sanofi’s Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Oelrich became head of Sanofi’s global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes & Cardiovascular on the Executive Committee of Sanofi. Since 2016, Oelrich has been a member of the Supervisory Board of the Berlin Institute of Health.

Olivier Mauroy-Bressier was appointed as Chief Financial Officer (CFO), Pharmaceuticals in October 2022.Olivier joined Bayer through the Aventis Crop Science acquisition in 2001, where he led Finance for the Central America Cluster. From 2002 through 2008, he held increasing responsibilities in the areas of Finance, Strategic Planning, Mergers & Acquisitions and Transfer Price Office for Bayer Crop Science in the US and the headquarters in Germany, before becoming CFO for Bayer in France in 2009. Between 2014 and 2016, Olivier headed the Global Controlling and Business Analytics organization for Bayer Consumer Care in the US before relocating to Basel, Switzerland to lead the establishment of Consumer Health division as CFO, coordinating and overseeing the subsequent turn-around of the business until end of 2019. Before taking his current role, Olivier served as Head of Internal Audit & Risk Management for the Bayer Group, dedicated to safeguarding and strengthening Bayer’s license to operate.Olivier holds a master’s degree in Corporate Finance from EDHEC Business School, France.

Dr. Rommel has served on the Askbio Board of Directors since 2021. He is the Executive Vice President, Global Head of Research & Development and Member of the Pharmaceuticals Leadership Team at Bayer, a role he has held since February 2021. From January 2014 to February 2021, Dr. Rommel served in various positions at Roche, culminating in his role as Senior Vice President, Global Head of Pharma Research and Early Development (pRED) Oncology. Prior to this, Dr. Rommel worked at Amgen where he held roles including Vice President of External Research and Development and Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech, from its inception to its acquisition by Takeda Pharmaceuticals. Dr. Rommel also contributes to the Board of Directors for BlueRock Therapeutics, Vividion Therapeutics, and CRISPR Therapeutics. He also serves on the Board of Trustees for the Max Planck Institute for Molecular Genetics. Dr. Rommel received his PhD in Molecular Oncology from the Max Planck Institute in Berlin, Germany, and the Institute of Medical Virology at the University of Zurich, Switzerland. In addition to his leadership roles, he lectured on biotechnology at the ETH Zurich, Switzerland, for several years. He has authored more than 70 publications, including papers in Science and Nature.

Gustavo Pesquin joined AskBio from Amneal Pharmaceuticals LLC, where he served as Chief Commercial Officer. Before that, Gustavo spent more than 10 years at Sanofi, a leading global pharmaceutical company, where he served in leadership roles of increasing responsibility, including North America Head for General Medicines as well as Global Head of the multi-billion dollar Diabetes and Cardiovascular Franchise. Prior to Sanofi, he held regional head, general manager, sales head, and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group. Pesquin earned an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and an undergraduate degree from Universidad Nacional de Cuyo in Argentina.

Dr. Mansuo Shannon joined AskBio in 2024 and serves as its Chief Scientific Officer (CSO). She is responsible for developing and implementing the company’s R&D strategy and leads all aspects of the discovery and development of AskBio’s gene therapy platform. Dr. Shannon also oversees the global teams charged with advancing that platform and provides scientific leadership to the CEO, Board of Directors, and company as a whole, in addition to being a key partner of the broader Bayer R&D leadership team and Bayer’s scientific community. Prior to joining AskBio, Dr. Shannon served as CSO at Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she established a robust gene therapy product portfolio in neurology and rare diseases. Earlier in her career, she spent more than 10 years at Eli Lilly, where she served in leadership roles of increasing responsibility and advanced multiple therapeutics into human clinical trials for Alzheimer’s disease and Parkinson’s disease. Dr. Shannon also previously held scientific leadership roles at Chugai/Roche Group and Merck.  Dr. Shannon earned her doctorate in Molecular Biology with Dr. Tom Shenk at Princeton University and conducted her postdoctoral research under Dr. Susumu Tonegawa (1987 Nobel Laureate) at the Massachusetts Institute of Technology.

Laura Sepp-Lorenzino, PhD, is a biotech executive with expertise in drug development, particularly in nucleic acid therapies. Laura is Principal of GNMmeds LLC, consulting on genomic medicine research and development.  She currently serves on the board of directors of Taysha Gene Therapies, AskBio Inc., URSA Medicines, the Alliance for Regenerative Medicine, and the American Society of Gene & Cell Therapy (ASGCT). She is the President Elect of the Oligonucleotide Therapeutics Society (2028–2029 term) and serves in their board.  Additionally, she chairs the scientific advisory board of Travin Bio and is an SAB member for Thermo Fisher Scientific, Inverna Therapeutics, U.K. Nucleic Acid Therapy Accelerator, and Arsenal Capital Partners. Previously, Laura was Chief Scientific Officer at Intellia Therapeutics (2019–2025), where she played a pivotal role in shaping the company’s strategic direction, fostering a robust and diversified CRISPR platform, and driving groundbreaking advances in in vivo genome editing. Under her leadership, Intellia demonstrated the first successful in vivo genome editing in humans and advanced two candidates into pivotal trials. Before Intellia, she served as Vice President, Head of Nucleic Acid Therapies at Vertex Pharmaceuticals, as well as Vice President and entrepreneur-in-residence at Alnylam Pharmaceuticals, and Executive Director of RNA Therapeutics at Merck & Co. Laura’s expertise extends beyond nucleic acid therapies, encompassing oncology drug discovery and development, honed through leadership roles at Merck West Point and Memorial Sloan-Kettering Cancer Center. She holds a professional degree in Biochemistry from the University of Buenos Aires, Argentina, and earned her MS and PhD in Biochemistry from New York University. She also contributes to the scientific community as an editorial board member of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.